Results 141 to 150 of about 229,703 (354)
Adrenotropic hormone (ACTH), aminopterin and eosinophil count. [PDF]
V. Traina
openalex +1 more source
The Eosinophil Response to Toxoids and its Inhibition by Antitoxin [PDF]
R. S. Speirs, Matthew Turner
openalex +1 more source
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E. Wechsler+34 more
wiley +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana+6 more
wiley +1 more source
Local Subcutaneous Eosinophil Leucocytic Reaction to the Inoculation of Isolated Normal or Tumour Cells in Mice [PDF]
Pankaj Goswami
openalex +1 more source
Objective The objective of this study was to investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods This multicenter cohort study was designed to emulate a target trial that studied 296 patients with ...
Yun Kyu Kim+7 more
wiley +1 more source
Blood and sputum biomarkers in COPD and asthma: a review [PDF]
Chronic obstructive pulmonary disease (COPD) and asthma are lung inflammatory diseases that represent major public health problems. The primary, and often unique, method to evaluate lung function is spirometry, which reflects disease severity rather than
Conti, V+8 more
core
MOTION PICTURE STUDIES ON DEGRANULATION OF HORSE EOSINOPHILS DURING PHAGOCYTOSIS [PDF]
G. T. L. Archer, James G. Hirsch
openalex +1 more source
Objective Raynaud's phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc ...
Iqtidar Hanif+32 more
wiley +1 more source